- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06824987
[Prova del dispositivo che non è approvato o cancellato dalla FDA degli Stati Uniti] (APPRECIATE)
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a Phase 2b study to assess efficacy and safety of AZD2373 involving 3 study treatment arms in Part A and 2 study treatment arms in Part B where participants and study personnel including study investigators are blinded to the assigned treatment.
Participants with 300 mg/g or greater UACR and eGFR ≥ 25mL/min/1.73m2 will be recruited into the study. Participants on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant will be excluded.
The study will have Part A and Part B. Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo. Part B (n = 40) will have a 4:1 randomization of participants to subgroups receiving every other week subcutaneous injections of 150 mg or placebo. Part B will begin after Part A is completely enrolled.
Both Part A and Part B will have same participant criteria and schedules. The SoA and visit schedule will not change for Part B.
All participants will remain in the study on treatment until the last participant has completed 30 weeks of treatment. The treatment duration will be up to minimum of 30 weeks of study treatment.
All participants will have the opportunity to enter the OLE study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Birmingham, Regno Unito, B15 2WB
- Research Site
-
Leicester, Regno Unito, Le5 4PW
- Research Site
-
Liverpool, Regno Unito, L22 0LG
- Research Site
-
London, Regno Unito, SE1 9RT
- Research Site
-
London, Regno Unito, NW3 2QG
- Research Site
-
London, Regno Unito, SW17 0QT
- Research Site
-
London, Regno Unito, SE5 8AZ
- Research Site
-
London, Regno Unito, SM5 1AA
- Research Site
-
London, Regno Unito, SW7 2AZ
- Research Site
-
Manchester, Regno Unito, M13 9WL
- Research Site
-
-
-
-
Alabama
-
Alabaster, Alabama, Stati Uniti, 35007
- Research Site
-
Birmingham, Alabama, Stati Uniti, 35205
- Research Site
-
Irondale, Alabama, Stati Uniti, 35210
- Research Site
-
-
Arizona
-
Surprise, Arizona, Stati Uniti, 85374
- Research Site
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211
- Research Site
-
Concord, California, Stati Uniti, 94520
- Research Site
-
Fremont, California, Stati Uniti, 94538
- Research Site
-
Gardena, California, Stati Uniti, 90247
- Research Site
-
Los Angeles, California, Stati Uniti, 90095
- Research Site
-
Valencia, California, Stati Uniti, 91355
- Research Site
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33487
- Research Site
-
Brandon, Florida, Stati Uniti, 33511
- Research Site
-
Miami, Florida, Stati Uniti, 33126
- Research Site
-
Miami, Florida, Stati Uniti, 33173
- Research Site
-
Orlando, Florida, Stati Uniti, 32808
- Research Site
-
Pompano Beach, Florida, Stati Uniti, 33060
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Research Site
-
Augusta, Georgia, Stati Uniti, 30912
- Research Site
-
Augusta, Georgia, Stati Uniti, 30909
- Research Site
-
Augusta, Georgia, Stati Uniti, 30904
- Research Site
-
Columbus, Georgia, Stati Uniti, 31904
- Research Site
-
Columbus, Georgia, Stati Uniti, 31901
- Research Site
-
Duluth, Georgia, Stati Uniti, 30096
- Research Site
-
Hinesville, Georgia, Stati Uniti, 31313
- Research Site
-
Lawrenceville, Georgia, Stati Uniti, 30046
- Research Site
-
Macon, Georgia, Stati Uniti, 31217
- Research Site
-
Macon, Georgia, Stati Uniti, 31210
- Research Site
-
Marietta, Georgia, Stati Uniti, 30067
- Research Site
-
Savannah, Georgia, Stati Uniti, 31406
- Research Site
-
Stockbridge, Georgia, Stati Uniti, 30281
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Research Site
-
Chicago, Illinois, Stati Uniti, 60643
- Research Site
-
Hinsdale, Illinois, Stati Uniti, 60521
- Research Site
-
Rockford, Illinois, Stati Uniti, 61107
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Research Site
-
Lafayette, Louisiana, Stati Uniti, 70508
- Research Site
-
New Orleans, Louisiana, Stati Uniti, 70112
- Research Site
-
Shreveport, Louisiana, Stati Uniti, 71103
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20889
- Research Site
-
Potomac, Maryland, Stati Uniti, 20854
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Research Site
-
Worcester, Massachusetts, Stati Uniti, 01608
- Research Site
-
-
Michigan
-
Lansing, Michigan, Stati Uniti, 48911
- Research Site
-
Roseville, Michigan, Stati Uniti, 48066
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Research Site
-
-
Mississippi
-
Columbus, Mississippi, Stati Uniti, 39705
- Research Site
-
Tupelo, Mississippi, Stati Uniti, 38801
- Research Site
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11203
- Research Site
-
Brooklyn, New York, Stati Uniti, 11221
- Research Site
-
Laurelton, New York, Stati Uniti, 11413
- Research Site
-
New York, New York, Stati Uniti, 10010
- Research Site
-
Rockville Centre, New York, Stati Uniti, 11570
- Research Site
-
The Bronx, New York, Stati Uniti, 10461
- Research Site
-
-
North Carolina
-
Cary, North Carolina, Stati Uniti, 27511
- Research Site
-
Durham, North Carolina, Stati Uniti, 27705
- Research Site
-
Fayetteville, North Carolina, Stati Uniti, 28304
- Research Site
-
Gastonia, North Carolina, Stati Uniti, 28054
- Research Site
-
Greenville, North Carolina, Stati Uniti, 27834
- Research Site
-
Jacksonville, North Carolina, Stati Uniti, 28546
- Research Site
-
Kinston, North Carolina, Stati Uniti, 28501
- Research Site
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Research Site
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45246
- Research Site
-
Columbus, Ohio, Stati Uniti, 43210
- Research Site
-
-
Pennsylvania
-
Bridgeville, Pennsylvania, Stati Uniti, 15017
- Research Site
-
Butler, Pennsylvania, Stati Uniti, 16001
- Research Site
-
Exton, Pennsylvania, Stati Uniti, 19341
- Research Site
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Research Site
-
-
South Carolina
-
Anderson, South Carolina, Stati Uniti, 29621
- Research Site
-
Columbia, South Carolina, Stati Uniti, 29203
- Research Site
-
Orangeburg, South Carolina, Stati Uniti, 29118
- Research Site
-
Spartanburg, South Carolina, Stati Uniti, 29306
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Research Site
-
Nashville, Tennessee, Stati Uniti, 37232
- Research Site
-
-
Texas
-
Conroe, Texas, Stati Uniti, 77304
- Research Site
-
Conroe, Texas, Stati Uniti, 77384
- Research Site
-
Dallas, Texas, Stati Uniti, 75234
- Research Site
-
Dallas, Texas, Stati Uniti, 75235
- Research Site
-
Houston, Texas, Stati Uniti, 77054
- Research Site
-
Katy, Texas, Stati Uniti, 77450
- Research Site
-
Mesquite, Texas, Stati Uniti, 75149
- Research Site
-
Pearland, Texas, Stati Uniti, 77584
- Research Site
-
San Antonio, Texas, Stati Uniti, 78212
- Research Site
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23510
- Research Site
-
Portsmouth, Virginia, Stati Uniti, 23708
- Research Site
-
Richmond, Virginia, Stati Uniti, 23298
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age: Male and female participants of African descent (including, but not limited to, Black, Black African, Black Caribbean, African American, Afro-Caribbean, Afro-Latino, West African, Mixed Black backgrounds, or other self-identified African diaspora heritage) aged 18 to 70 years, inclusive at the time of informed consent.
- Participants who have high-risk APOL1 genotype (G1/G1; G1/G2; G2/G2). The screening period can be extended if there are delays related to the shipment, handling, or processing of genotype results.
- A geometric mean UACR ≥ 300 mg/g calculated based on the mean of readings taken from 3 FMV urine samples collected on 3 consecutive days. Since the mean will be assessed for eligibility, any of the 3 readings may fall below 300 mg/g.
- eGFR ≥ 25 mL/min/1.73m2.
- Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
Participants with diagnosis of Type 1 diabetes mellitus.
-
Body Mass Index > 45 kg/m2.
-
SBP > 180 mmHg/DBP > 110 mmHg (measured when the participant is considered to be at steady state, and preferably when they have taken their BP medications that same day).
-
QTcF > 470 ms, except participants with bundle branch block who should excluded if QTcF> 480 ms.
-
Acute coronary syndrome/Acute myocardial infraction with or without any coronary intervention within 6 months.
-
Transient ischaemic attack/ stroke within 3 months.
-
High grade (second to third) degree AV block or clinically significant sinus node dysfunction untreated with pacemaker.
-
A history of ventricular arrhythmias requiring treatment.
-
Participants with Type 2 diabetes mellitus must be excluded if ANY of the following conditions are present:
- Current or past use of insulin for more than 3 months and/or any maintenance therapy with insulin within 2 months of screening.
- Screening Haemoglobin A1c > 8.0%
- Receiving more than one anti-hyperglycaemic agent (excluding SGLT inhibitors and GLP-1 receptor agonists is permitted if prescribed for a purpose other than glycaemic control which can be taken in addition to one other anti-hyperglycaemic agent).
-
Participant on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant.
-
History or serologic evidence of autoimmune-mediated glomerular disease including but not limited to: lupus nephritis (positive lupus serology), ANCA associated vasculitis (antineutrophil cytoplasmic antibody), membranous nephropathy (anti-phospholipase A2 receptor antibody or other autoantibody associated with membranous nephropathy), anti-GBM disease (anti-GBM antibody), or IgA nephropathy.
-
Another underlying cause of kidney disease that is not associated with APOL1, including but not limited to polycystic kidney disease or, congenital anomalies of the kidney and urinary tract.
-
History of a diagnosed coagulopathy, a major unexplained bleeding event, or other high-risk bleeding diathesis.
-
A history of trypanosomiasis or leishmaniasis.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Part A - Placebo group
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
Accessorized Pre-Filled Syringe (Solution for injection). The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. |
|
Sperimentale: Part A - AZD2373 - Arm 1
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Sperimentale: Part A - AZD2373 - Arm 2
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Sperimentale: Part B - AZD2373 Arm 1
Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Comparatore placebo: Part B - Placebo group
Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
Accessorized Pre-Filled Syringe (Solution for injection). The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at Week 30
|
To assess the effect of AZD2373 versus placebo in reducing albuminuria |
From Baseline at Week 30
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the effect of AZD2373 versus placebo in reducing albuminuria |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Lasso di tempo: From Baseline at Week 30
|
To assess the effect of AZD2373 versus placebo in reducing proteinuria |
From Baseline at Week 30
|
|
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the effect of AZD2373 versus placebo in reducing proteinuria |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at Week 30
|
To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment |
From Baseline at Week 30
|
|
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
eGFR slope
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess pooled AZD2373 doses versus placebo on eGFR change |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Incidence of development of ADA and ADA titer (if participants are ADA-positive)
Lasso di tempo: During treatment (up to Week 30) and follow-up (up to 12 weeks)
|
To evaluate the immunogenicity of AZD2373 |
During treatment (up to Week 30) and follow-up (up to 12 weeks)
|
|
Plasma concentration
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To evaluate the PK of AZD2373 |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Adverse Events (AEs), Serious Adverse Events (SAEs), and Drug Adverse Events (DAEs).
Lasso di tempo: From baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the safety and tolerability of ranging doses of AZD2373. These events will be collected according to the timepoints specified in the schedule of assessments, starting from the time of signing the Informed Consent Form (ICF). |
From baseline at the End of Treatment (Until the last participant completes Week 30)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- D6800C00005
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .